IRIS PubliCatt

Foa, Robin
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 1.274
EU - Europa 635
AS - Asia 258
OC - Oceania 5
AF - Africa 3
SA - Sud America 3
Continente sconosciuto - Info sul continente non disponibili 1
Totale 2.179
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.272
SE - Svezia 232
IT - Italia 149
CN - Cina 116
IE - Irlanda 66
SG - Singapore 66
DE - Germania 52
PL - Polonia 52
ID - Indonesia 38
RU - Federazione Russa 22
IN - India 21
FR - Francia 20
GB - Regno Unito 13
UA - Ucraina 11
TR - Turchia 8
FI - Finlandia 7
AU - Australia 5
CH - Svizzera 3
AR - Argentina 2
CA - Canada 2
CI - Costa d'Avorio 2
GR - Grecia 2
IR - Iran 2
JP - Giappone 2
KR - Corea 2
AT - Austria 1
BE - Belgio 1
BR - Brasile 1
CY - Cipro 1
CZ - Repubblica Ceca 1
EG - Egitto 1
EU - Europa 1
IL - Israele 1
LI - Liechtenstein 1
LT - Lituania 1
LU - Lussemburgo 1
VN - Vietnam 1
Totale 2.179
Salva come PNG Salva come JPEG
Città #
Chandler 193
Ashburn 59
Dublin 58
Warsaw 52
Singapore 50
New York 47
Dearborn 45
Florence 45
Jakarta 38
Princeton 28
Beijing 26
San Mateo 25
Wilmington 23
Redwood City 22
Milan 21
Nanjing 20
Albany 16
Minneapolis 16
Moscow 15
Pune 14
Nanchang 13
Boston 12
Houston 12
Norwalk 12
Kunming 11
Marseille 9
Chicago 8
Hefei 8
Izmir 8
Cattolica 7
Fairfield 7
Los Angeles 7
Frankfurt am Main 6
Garden City 6
Rome 6
Changsha 5
Jacksonville 5
Seattle 5
Benalla 4
Bologna 4
Engelhard 4
Genoa 4
Munich 4
Redmond 4
Shenyang 4
Vicopisano 4
Falls Church 3
Fremont 3
Helsinki 3
London 3
Mountain View 3
Padova 3
Sesto Fiorentino 3
Washington 3
Abidjan 2
Andover 2
Bari 2
Buenos Aires 2
Durham 2
Gurgaon 2
Hebei 2
Jiaxing 2
Jinan 2
Lappeenranta 2
Lawrence 2
Reggio Emilia 2
Rivalta Di Torino 2
Seoul 2
Turin 2
Verona 2
Woodbridge 2
Ardabil 1
Atlanta 1
Auburn Hills 1
Belo Horizonte 1
Berlin 1
Bern 1
Billings 1
Bremen 1
Brescia 1
Brno 1
Brussels 1
Busto Arsizio 1
Charlotte 1
Chengdu 1
Chennai 1
Chiswick 1
Cleveland 1
Como 1
Dong Ket 1
Dubendorf 1
Edinburgh 1
Gossolengo 1
Hendon 1
Kish 1
Lanzhou 1
Luxembourg 1
Malo 1
Mcallen 1
Naples 1
Totale 1.079
Salva come PNG Salva come JPEG
Nome #
Analysis of the chronic lymphocytic leukemia coding genome: role of NOTCH1 mutational activation 592
Prognostic implications of additional genomic lesions in adult Philadelphia chromosome-positive acute lymphoblastic leukemia 118
Outcome of Allogeneic Hematopoietic Stem Cell Transplantation in Adult Patients with Philadelphia Positive Acute Lymphoblastic Leukemia in the Era of Tyrosine Kinase Inhibitors. A Registry-Based Study of the Italian Blood and Marrow Transplantation Society (Gitmo) 101
Chlorambucil plus rituximab as front-line therapy for elderly and/or unfit chronic lymphocytic leukemia patients: Correlation with biologically-based risk stratification 79
Biological and clinical implications of BIRC3 mutations in chronic lymphocytic leukemia 68
Bendamustine in combination with rituximab for elderly patients with previously untreated B-cell chronic lymphocytic leukemia: A retrospective analysis of real-life practice in Italian hematology departments. 63
Markers of myeloproliferative diseases in childhood polycythemia vera and essential thrombocythemia 62
Efficacy of bendamustine and rituximab as first salvage treatment in chronic lymphocytic leukemia and indirect comparison with ibrutinib: a GIMEMA, ERIC and UK CLL FORUM study 61
Assessment of the 4-factor score: Retrospective analysis of 586 CLL patients receiving ibrutinib. A campus CLL study 60
Factors predicting survival in chronic lymphocytic leukemia patients developing Richter syndrome transformation into Hodgkin lymphoma 59
Comparison of ibrutinib and idelalisib plus rituximab in real-life relapsed/resistant chronic lymphocytic leukemia cases 57
Anti-HLA donor-specific antibodies in allogeneic stem cell transplantation: management and desensitization protocol 55
Preexisting and treatment-emergent autoimmune cytopenias in patients with CLL treated with targeted drugs 55
Survival risk score for real-life relapsed/refractory chronic lymphocytic leukemia patients receiving ibrutinib. A campus CLL study 53
HIF-1α is overexpressed in leukemic cells from TP53-disrupted patients and is a promising therapeutic target in chronic lymphocytic leukemia 52
A scoring system to predict the risk of atrial fibrillation in chronic lymphocytic leukemia 50
Prognostic impact and risk factors of infections in patients with chronic lymphocytic leukemia treated with ibrutinib 45
Comparison between the CLL-IPI and the Barcelona-Brno prognostic model: Analysis of 1299 newly diagnosed cases 44
Ponatinib as second-line treatment in chronic phase chronic myeloid leukemia patients in real-life practice. 44
Effectiveness of ibrutinib as first-line therapy for chronic lymphocytic leukemia patients and indirect comparison with rituximab-bendamustine: Results of study on 486 cases outside clinical trials 43
Efficacy of bendamustine and rituximab in unfit patients with previously untreated chronic lymphocytic leukemia. Indirect comparison with ibrutinib in a real-world setting. A GIMEMA-ERIC and US study 43
Efficacy of idelalisib and rituximab in relapsed/refractory chronic lymphocytic leukemia treated outside of clinical trials. A report of the Gimema Working Group 41
TP53 disruption as a risk factor in the era of targeted therapies: A multicenter retrospective study of 525 chronic lymphocytic leukemia cases 41
Validation of a survival-risk score (SRS) in relapsed/refractory CLL patients treated with idelalisib–rituximab 35
Management of chronic lymphocytic leukemia in Italy during a one year of the COVID-19 pandemic and at the start of the vaccination program. A Campus CLL report 34
COVID-19 severity and mortality in patients with chronic lymphocytic leukemia: a joint study by ERIC, the European Research Initiative on CLL, and CLL Campus 33
Validation of a biological score to predict response in chronic lymphocytic leukemia patients treated front-line with bendamustine and rituximab 31
Predictive value of the CLL-IPI in CLL patients receiving chemo-immunotherapy as first-line treatment 29
Chronic lymphocytic leukemia management in Italy during the COVID-19 pandemic: A Campus CLL report 29
Long-term benefit of IGHV mutated patients in a real-life multicenter cohort of FCR-treated chronic lymphocytic leukemia 27
Prediction of outcomes in chronic lymphocytic leukemia patients treated with ibrutinib: Validation of current prognostic models and development of a simplified three-factor model 24
Obinutuzumab plus chlorambucil versus ibrutinib in previously untreated chronic lymphocytic leukemia patients without TP53 disruptions: A real-life CLL campus study 22
Clinical impact of TP53 disruption in chronic lymphocytic leukemia patients treated with ibrutinib: a campus CLL study 21
Efficacy of front-line ibrutinib versus fludarabine, cyclophosphamide, and rituximab in patients with chronic lymphocytic leukemia: A retrospective multicenter “Real-World” study 19
Thrombotic and bleeding complications in patients with chronic lymphocytic leukemia and severe COVID-19: a study of ERIC, the European Research Initiative on CLL 19
BH3 mimetics in relapsed and refractory adult acute lymphoblastic leukemia: a Campus ALL real-life study 7
Lymphadenopathy as a predictor of progression during venetoclax treatment in chronic lymphocytic leukemia. A campus chronic lymphocytic leukemia study 6
Totale 2.222
Salva come PNG Salva come JPEG
Categoria #
all - tutte 10.078
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 10.078
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020168 0 0 0 13 15 32 30 16 19 18 16 9
2020/202183 2 11 3 7 12 10 8 1 5 11 8 5
2021/2022287 9 3 47 36 37 6 2 32 10 9 62 34
2022/2023510 68 76 34 59 41 68 15 32 69 7 31 10
2023/2024878 20 81 30 542 20 100 8 10 2 11 16 38
2024/2025107 24 16 49 18 0 0 0 0 0 0 0 0
Totale 2.222